Marc Mansour Selected Research

Communicable Diseases (Infectious Diseases)

1/2020	A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model.
1/2020	Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
1/2017	Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.
8/2010	A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Mansour Research Topics

Disease

17	Neoplasms (Cancer) 01/2020 - 06/2006
4	Communicable Diseases (Infectious Diseases) 01/2020 - 08/2010
4	Prostatic Neoplasms (Prostate Cancer) 01/2014 - 07/2012
2	Sepsis (Septicemia) 01/2021 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2017 - 08/2011
2	Ovarian Neoplasms (Ovarian Cancer) 08/2015 - 04/2010
2	Injection Site Reaction 01/2014 - 08/2012
2	Hypoxia (Hypoxemia) 08/2004 - 02/2002
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 01/2022
1	Vaccinia 01/2022
1	Malaria 01/2020
1	Persistent Infection 01/2020
1	Cyanosis 01/2018
1	Immune Complex Diseases (Immune Complex Disease) 01/2018
1	Genomic Instability 11/2017
1	Human Influenza (Influenza) 01/2017
1	Anthrax 01/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2011
1	Hepatitis B 10/2010
1	Carcinoma (Carcinomatosis) 04/2010
1	Whooping Cough (Pertussis) 10/2007
1	Infections 10/2007
1	Tetanus 10/2007
1	Diphtheria 10/2007
1	Melanoma (Melanoma, Malignant) 04/2007
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2006

Drug/Important Bio-Agent (IBA)

19	VaccinesIBA 01/2022 - 06/2006
16	Peptides (Polypeptides)IBA 01/2022 - 06/2006
10	AntigensIBA 01/2022 - 04/2007
7	Cancer VaccinesIBA 01/2016 - 04/2010
5	EmulsionsIBA 06/2016 - 06/2006
4	DPX-0907IBA 01/2014 - 04/2010
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2014 - 06/2007
3	Immunologic Factors (Immunomodulators)IBA 01/2022 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 11/2017 - 06/2006
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 01/2014
3	Protein Subunit VaccinesIBA 01/2014 - 04/2010
3	Liposomes (Liposome)IBA 10/2007 - 06/2006
2	LigandsIBA 01/2021 - 01/2020
2	Monoclonal AntibodiesIBA 01/2020 - 01/2020
2	Malaria VaccinesIBA 01/2020 - 01/2020
2	2-Methyl-4-chlorophenoxyacetic Acid (MCPA)IBA 01/2016 - 01/2014
1	Nucleic AcidsIBA 01/2022
1	AntibodiesIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Vaccine AdjuvantsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2018
1	aluminum sulfate (alum)IBA 01/2018
1	Complement C3 (C3 Complement)IBA 01/2018
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2018
1	Poly I-CIBA 01/2017
1	Anthrax Vaccines (Vaccines, Anthrax)IBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	SurvivinIBA 08/2015
1	Biomarkers (Surrogate Marker)IBA 01/2015
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2014
1	CytokinesIBA 01/2013
1	Transcription Factors (Transcription Factor)IBA 08/2011
1	Messenger RNA (mRNA)IBA 08/2011
1	afimoxifene (hydroxytamoxifen)IBA 08/2011
1	Recombinant ProteinsIBA 08/2010
1	Bacterial AntigensIBA 08/2010
1	Nucleic Acid-Based VaccinesIBA 08/2010
1	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 10/2007
1	Molecular Chaperones (Chaperone, Molecular)IBA 02/2002

Therapy/Procedure

7	Immunotherapy 01/2020 - 06/2007
4	Therapeutics 01/2020 - 04/2007
1	Punctures 01/2021
1	Ligation 01/2021
1	Drug Therapy (Chemotherapy) 08/2011
1	Heterologous Transplantation (Xenotransplantation) 08/2004